ID Biomedical completes Fluviral trial enrollment

ID Biomedical of Canada has completed the enrollment of 1,000 subjects for the clinical trial of its influenza vaccine, Fluviral, intended to support accelerated domestic approval.

The randomized, double-blind, comparator-controlled study is designed to evaluate the safety and immunogenicity of the vaccine in healthy adults. The company has expanded this trial from the original population of 300.

The firm is also conducting a similar clinical study in Canada with 658 people in two age groups, 50-64 years old and over 64 years of age; these data will also be filed in support of a US authorization.